1,100
Participants
Start Date
May 16, 2022
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2027
Sampling
This is an observational study. Consequently, study participation does not alter the therapy of the treated disease. Blood will be drawn from patients at several time points during and after radiotherapy (RT) and therapy with immune checkpoint inhibitor (ICI) for detailed immunomonitoring of the patients. In addition, faeces and sputum of the patients for microbiomic and metabolomic measures will be collected. Whenever possible, adequate tissue samples are taken from the center of the tumor and a biopsy is taken from the edge of the tumor including the adjacent mucosa in the nearby area without affecting the pathological assessment (study group). Blood, faeces and sputum will be taken from patients of the control group prior to surgery. After surgery, only blood will be taken.
RECRUITING
ENT - Head and Neck Surgery Department, Erlangen
RECRUITING
Maxillo-Facial-Surgery Department, Erlangen
RECRUITING
Radiation Oncology Department, Erlangen
University Hospital Erlangen
OTHER
University Hospital Regensburg
OTHER
University Hospital Augsburg
OTHER
University of Erlangen-Nürnberg Medical School
OTHER